INDV

시장 영업 전: 13.44 -0.23 -1.68%

Indivior Plc (INDV)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

Indivior Plc Stock (INDV) Company Profile

Indivior Plc

Healthcare (1170)

804-379-1090

234 BATH ROAD, SLOUGH, BERKSHIRE

최신 SEC 제출 서류

INDV's Discussions on Twitter

INDV을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
INDV Indivior Plc	13.67	1.50B	1.12B	5.00M	-383.00M	0.01
HLN Haleon Plc Adr	10.93	50.62B	14.35B	1.85B	0	0.4023
ZTS Zoetis Inc	168.59	73.64B	9.29B	2.52B	2.28B	5.57
RDHL Redhill Biopharma Ltd Adr	1.92	4.12M	35.75M	11.57M	-26.25M	-3.8069
TAK Takeda Pharmaceutical Co Adr	15.03	45.57B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	17.52	20.82B	16.54B	-1.64B	749.00M	-1.45

Indivior Plc Stock (INDV) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-01-28	개시	Rodman & Renshaw	Buy
2024-07-23	개시	Piper Sandler	Overweight
2024-04-03	개시	Craig Hallum	Buy
2023-07-13	개시	Northland Capital	Outperform

Indivior Plc 주식(INDV)의 최신 뉴스

Indivior Plc (INDV) 재무 분석

Indivior Plc (INDV)

Indivior Plc Stock (INDV) Company Profile

INDV을(를) 다른 주식과 비교

Indivior Plc Stock (INDV) Upgrades & Downgrades

Indivior Plc 주식(INDV)의 최신 뉴스

Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference - GlobeNewswire Inc.

Indivior to delist from London Stock Exchange, maintain primary listing on Nasdaq - MSN

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Indivior PLC To Contact The Firm - ACCESS Newswire

Indivior’s exit comes as no surprise - The Times

Levi & Korsinsky Notifies Indivior PLC Investors of a Class Action Lawsuit and Upcoming DeadlineINDV - ACCESS Newswire

Opioid Use Disorder Market Projected to Witness Massive GrowthIndivior PLC, Alkermes plc - openPR.com

Trending tickers: The latest investor updates on Tesla, Palantir, Sanofi, Babcock and Indivior - Yahoo

Kalkine : Indivior’s Exit from London Exchange Impacts FTSE 100 Pharmaceutical Landscape - Kalkine Media

Indivior to delist from London Stock Exchangewill stay on Nasdaq - Insider Media Ltd

Drug maker Indivior joins London Stock Exchange exodus, 2 Jun 2025 11:00 - Shares Magazine

Kalkine : Indivior’s FTSE 100 Sector Shift: Delisting from London to Focus on Nasdaq Listing - Kalkine Media

Kalkine: Indivior Exits London as FTSE 100 Firm Focuses on Nasdaq - Kalkine Media

FTSE pharma giant joins London stock market exodus - The Telegraph

Indivior (INDV) Delists from London to Focus on U.S. Market - GuruFocus

Indivior brings curtain down on turbulent 11-year run in London - Proactive financial news

Indivior drops London listing to focus on U.S. market By Investing.com - Investing.com Nigeria

Indivior To Delist From LSE To Better Align With US Focused Business - Nasdaq

Indivior to cancel secondary listing in London - Sharecast.com

Indivior Plans to Cancel London Listing After Moving Primary to US - Bloomberg

Drug maker Indivior to abandon London stock market for the US - Yahoo

Indivior to Cancel London Stock Exchange Listing, Focuses on Nasdaq - TipRanks

Indivior to Cancel Secondary Listing on London Stock Exchange, Maintains Primary Nasdaq Listing | Indivior Stock News - paginasiete.bo

Indivior to delist from London Stock Exchange, maintain Nasdaq listing - marketscreener.com

Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained | INDV Stock News - GuruFocus

Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained - Bluefield Daily Telegraph

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 1, 2024 in Indivior PLC LawsuitINDV - ACCESS Newswire

Indivior Announces Patrick Barry as Chief Commercial Officer - The Malaysian Reserve

Indivior appoints Patrick Barry as Chief Commercial Officer By Investing.com - Investing.com South Africa

Indivior Announces Patrick Barry as Chief Commercial Officer | I - GuruFocus

Indivior appoints Patrick Barry as Chief Commercial Officer - Investing.com India

Indivior Announces Patrick Barry as Chief Commercial Officer | INDV Stock News - GuruFocus

Indivior PLC (INDV) Stock Analysis: A 30% Upside Potential Amidst Strong Buy Ratings - DirectorsTalk Interviews

Investors in Indivior (LON:INDV) have seen solid returns of 156% over the past five years - Yahoo Finance

How To Trade (INDV) - news.stocktradersdaily.com

Indivior PLC (LON:INDV) Held Back By Insufficient Growth Even After Shares Climb 26% - simplywall.st

Naloxone Market Projected To Witness Massive Growth, 2025-2032 - openPR.com

Court of Appeal upholds representative action strike out in Wirral Council v Indivior/Reckitt, but claimant applies for permission to appeal to Supreme Court - stewartslaw.com

Indivior PLC Aligns CEO Compensation with Long-Term Performance Goals - TipRanks

Indivior to Participate in Upcoming Investor Events - StreetInsider

Indivior to Participate in Upcoming Investor Events | INDV Stock News - GuruFocus

Indivior announces participation in investor conferences By Investing.com - Investing.com India

Indivior to Engage with Investors at Key Healthcare Conferences - TipRanks

Indivior to Participate in Upcoming Investor Events – Company Announcement - Financial Times

Drug Addiction Treatment Market Projected To Witness Massive - openPR.com

(INDV) Long Term Investment Analysis - news.stocktradersdaily.com

Drug Abuse Treatment Market Grows Amid Rising Substance Abuse - openPR.com

Indivior advances GABA-B PAM program for substance use disorders through IND-enabling studies - BioWorld MedTech

Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies - Yahoo

Shareholders of Indivior PLC Should Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your RightsINDV - ACCESS Newswire

Indivior Plc (INDV) 재무 분석

매출

순이익

현금흐름

주당 순 이익

INDV과 유사한 종목